CDK9 inhibition blocks the initiation of PINK1-PRK1-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic efficacy of treatments involving mitochondrial dysfunction in HCC. Here, BNIP3 is linked to hepatocellular carcinoma.